Adriamycin-induced nephropathy models: elucidating CKD pathophysiology and advancing therapeutic strategies
Experimental Animals · 2025 · 74 (2) · 132-142
DOI: 10.1538/expanim.24-0133 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Experimental Animals, 2025. Verfasst von Masaki Watanabe und 2 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Laboratory Animal Science and Medicine, School of Veterinary Medicine, Kitasato University, 35-1 Higashi-23, Towada, Aomori 034-8628, J…. Hauptthemen laut MEDLINE: Doxorubicin, Renal Insufficiency, Chronic, Disease Models, Animal. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The Adriamycin-induced nephropathy (AN) model plays a crucial role in advancing our understanding of and research on chronic kidney disease (CKD). This review outlines methodologies for generating AN models in mice and rats, discusses their pathophysiologic and molecular characteristics, highlights their advantages and limitations, describes therapeutic interventions that have been evaluated in these models, and presents future research perspectives. The AN model replicates key features observed in human CKD, such as proteinuria, podocyte injury, glomerulosclerosis, and tubulointerstitial fibrosis. Notably, genetic factors significantly influence the onset and severity of AN, with mutations in the Prkdc gene linked to nephrotoxicity and systemic toxicity. To evaluate therapeutic interventions for CKD, agents such as ACE inhibitors, corticosteroids, and SGLT2 inhibitors have been tested in the AN model, demonstrating promising renoprotective effects. However, the systemic toxicity of Adriamycin and variability across models pose limitations, highlighting the need for caution when translating findings to human CKD. Future advancements in genetic engineering and the application of CRISPR-Cas9 technology are expected to improve the fidelity of AN models to human disease. Additionally, discovery of biomarkers by using the AN model enables us to improve early diagnosis. These efforts are anticipated to deepen our understanding of CKD pathophysiology and contribute to developing more effective diagnostic tools and targeted therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Laboratory Animal Science and Medicine, School of Veterinary Medicine, Kitasato University, 35-1 Higashi-23, Towada, Aomori 034-8628, Japan.
Zitieren
APA
Watanabe, M., Takimoto, H. R., & Sasaki, N. (2025). Adriamycin-induced nephropathy models: elucidating CKD pathophysiology and advancing therapeutic strategies. Experimental Animals, 74(2), 132-142. https://doi.org/10.1538/expanim.24-0133
Vancouver
Watanabe M, Takimoto HR, Sasaki N. Adriamycin-induced nephropathy models: elucidating CKD pathophysiology and advancing therapeutic strategies. Experimental Animals. 2025;74(2):132-142. doi:10.1538/expanim.24-0133
BibTeX
@article{Watanabe2025,
author = {Watanabe, Masaki and Takimoto, Hayato R and Sasaki, Nobuya},
title = {Adriamycin-induced nephropathy models: elucidating CKD pathophysiology and advancing therapeutic strategies},
journal = {Experimental Animals},
year = {2025},
volume = {74},
number = {2},
pages = {132--142},
doi = {10.1538/expanim.24-0133}
}
EUVIMED